Canada Approves Pfizer’s RSV Vaccine
The vaccine was approved for older adults and infants through maternal immunization.
The vaccine was approved for older adults and infants through maternal immunization.
A Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) plus chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline.
Shanghai became the first city to initiate booster vaccination by inhalation for adults aged 18+ using aerosol drug delivery technology from Aerogen.
The FDA has approved a generic version of roflumilast manufactured by Zydus Pharmaceuticals USA Inc for the treatment of COPD.
Read MoreHealth Canada has granted authorization for Novavax Inc’s COVID-19 vaccine “Nuvaxovid” for adults age 18 and older.
Read MoreNovavax Inc’s COVID-19 vaccine demonstrated 80% efficacy overall in a study of over 2,000 pediatric patients when the Delta variant was the predominant circulating strain in the US.
Read MoreNovavax Inc has received authorizations for its COVID-19 vaccine NVX-CoV2373 (brand name Nuvaxovid) in Great Britain and in New Zealand, the company reports.
Read MoreAstraZeneca reports that its COVID-19 vaccine (Vaxzevria), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.
Read MoreVaccines conferred protection from all COVID-19 variants but there was reduced antibody neutralization of both the Beta and Delta variants.
Read MoreThe European Commission approved Merck’s VaxNeuvance (Pneumococcal 15-valent Conjugate Vaccine) for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Read MorePositive results from the first co-administration study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine have been published in The Lancet Respiratory Medicine.
Read MoreMerck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Read MoreNovavax has completed its rolling regulatory submission for authorization of its NVX-CoV2373 COVID-19 vaccine candidate in the United Kingdom.
Read MoreThe French pharmaceutical company Valneva announced positive topline results from the Phase 3 trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Read MoreModerna’s COVID-19 vaccine booster (mRNA-1273 50µg dose level) induced robust antibody responses of more than 40 times against the Delta variant (B.1.617.2), according to Phase 2 clinical data reported by the company.
Read More